亿腾嘉和(06998):EDP167 II期临床试验完成首例受试者给药

智通财经
Feb 09

智通财经APP讯,亿腾嘉和(06998)发布公告,旗下小核酸创新药EDP167 II期临床试验成功完成首例受试者给药。

EDP167 II期临床试验是一项针对纯合子家族性高胆固醇血症(HoFH)成人患者的多中心、剂量探索、开放标签的试验,旨在评估EDP167在HoFH患者中的疗效和安全性,其主要终点为首次给药24周后低密度脂蛋白胆固醇(LDL-C)水平相较基线的变化,预计于2026年第四季度完成主要终点的评估。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10